|Bid||4.50 x 3000|
|Ask||9.50 x 1000|
|Day's Range||6.77 - 6.90|
|52 Week Range||0.32 - 16.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
GERMANTOWN, Md., Aug. 15, 2018-- Orgenesis Inc., a manufacturer, service provider, and developer of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer ...
Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Atvio Biotech Ltd., which is wholly-owned by Orgenesis’ Masthercell Global subsidiary, and Secant Group are collaborating to develop and commercialize biodegradable and injectable scaffold technologies for use in Orgenesis’ advanced cell therapies. Under the agreement, Secant Group is to engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable polymer microparticles, while Atvio Biotech will provide expertise in cell coatings, cell production, process development and support services. The collaboration will be financed in part through a $1.8 million grant from the Israel-U.S. Binational Industrial R&D (BIRD) Foundation, as well as additional funding provided by Orgenesis and Secant Group. Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform, including its Autologous Insulin Producing (“AIP”) cell technology for patients with Type 1 Diabetes, acute pancreatitis and other insulin deficient diseases.
LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen.
Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal second quarter ended May 31, 2018. Vered Caplan, CEO of Orgenesis, commented, “I am pleased to report that we not only achieved a 73% increase in sales compared to the same quarter last year, but we generated a 51% sequential increase compared to the first quarter of fiscal 2018. We attribute this growth to the continued addition of new customers and expansion of services among our existing customers, especially as it relates to manufacturing of CAR T-cell therapies.
Inc. to fund the biopharmaceutical company’s new contract development and manufacturing subsidiary. Orgenesis said Great Point would provide up to $25 million in Masthercell Global Inc. to “fund, assist and advise” on the launch of the new subsidiary’s U.S. operations and on its global expansion initiatives. As part of the deal, Orgenesis folded an existing contract development and manufacturing subsidiary in Belgium into the new business.
Consolidates Global CDMO Business Including Belgian Subsidiary MaSTherCell S.A., Israeli Partner Atvio Biotech and Korean Partner Curecell Co. In connection with the transaction, Orgenesis has consolidated its global CDMO network into Masthercell Global, including its flagship Belgian-based CDMO subsidiary, MaSTherCell S.A. (“Masthercell Belgium”). Orgenesis also acquired Atvio Biotech Ltd. (“Atvio”), the Company’s Israel-based CDMO partner since May 2016, and Curecell Co. Ltd. (“Curecell”), the Company’s Korea-based CDMO partner since March 2016. Both Atvio and Curecell are to become subsidiaries of Masthercell Global.
Orgenesis Inc. (ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that it has been added to the FTSE Russell Microcap® Index effective at the market open today, June 25. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell U.S. Indexes primarily by objective, market-capitalization rankings and style attributes. The Russell Microcap® Index is one of the most widely used small cap indexes by institutional investors. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider.
I am going to take a deep dive into Orgenesis Inc’s (NASDAQ:ORGS) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structure isRead More...
Orgenesis Inc. (ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that their Israeli Contract Development and Manufacturing Organization (CDMO) partner, Atvio Biotechnology, will be featured on a roundtable at the 2018 BIO International Convention being held June 4 - 7 in Boston, Massachusetts. Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer of Atvio, will speak on the panel, “Feeding the Demand for Cell and Gene Therapy Production,” a topic recently highlighted by FDA Commissioner Scott Gottlieb.
If you are looking to invest in Orgenesis Inc’s (NASDAQ:ORGS), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
Leading Orgenesis Inc (NASDAQ:ORGS) as the CEO, Vered Caplan took the company to a valuation of US$108.90M. Understanding how CEOs are incentivised to run and grow their company is anRead More...
Measuring Orgenesis Inc’s (NASDAQ:ORGS) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceed expectations,Read More...